Procter & Gamble Health Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Press release for the quarter ended September 30, 2025".
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Health Limited announced its Q2 FY26 results, reporting sales of ₹319 crores, up 3% year-on-year, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ₹89 crores, up 8% year-on-year, supported by top-line growth. Key growth drivers included a consumer communication campaign for brands Evion and Seven Seas, along with new product launches such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. The company highlighted continued investment in supply chain capabilities and science-backed innovation. This marks the second consecutive quarter of balanced growth across both revenue and profit.
Steady mid-single-digit revenue growth combined with high-single-digit profit growth signals consistent operational execution, likely to be viewed positively by shareholders. The combination of new product launches and brand-building initiatives supports confidence in sustained near-term momentum.